Karyopharm Therapeutics Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 9.53. In total, the insiders bought 3 054 022 and sold 1 910 543 KPTI shares in the last 100 trades.

Insider Power

(Last 100 transactions)
9.53
Buy 3 054 022 Shares
Sell 1 910 543 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 07, 2024 Common Stock Sell Pakianathan Deepika 2 240
Jun 06, 2024 Common Stock Sell Pakianathan Deepika 117 307
Jun 06, 2024 Common Stock Sell Pakianathan Deepika 1 145
Jun 05, 2024 Common Stock Sell Pakianathan Deepika 463 518
Jun 05, 2024 Common Stock Sell Pakianathan Deepika 4 526
Jun 04, 2024 Common Stock Sell Mason Michael 652
Jun 04, 2024 Common Stock Sell Paulson Richard A. 3 592
Jun 04, 2024 Common Stock Sell Pakianathan Deepika 337 742
Jun 04, 2024 Common Stock Sell Pakianathan Deepika 3 298
Jun 03, 2024 Common Stock Sell Pakianathan Deepika 357 256
Jun 03, 2024 Common Stock Sell Pakianathan Deepika 3 488
May 31, 2024 Common Stock Sell Pakianathan Deepika 202 418
May 31, 2024 Common Stock Sell Pakianathan Deepika 1 976
May 29, 2024 Nonstatutory Stock Option (right to buy) Buy Su Zhen 50 587
May 29, 2024 Nonstatutory Stock Option (right to buy) Buy Schor Chen 69 000
May 29, 2024 Nonstatutory Stock Option (right to buy) Buy Pakianathan Deepika 69 000
May 29, 2024 Nonstatutory Stock Option (right to buy) Buy Oliger Christy J. 69 000
May 29, 2024 Nonstatutory Stock Option (right to buy) Buy Mirza Mansoor Raza 69 000
May 29, 2024 Nonstatutory Stock Option (right to buy) Buy Greene Barry E 69 000
May 29, 2024 Nonstatutory Stock Option (right to buy) Buy Bohlin Garen G 69 000
May 06, 2024 Common Stock Sell Paulson Richard A. 3 576
Apr 22, 2024 Common Stock Sell Rangwala Reshma 6 789
Apr 04, 2024 Common Stock Sell Paulson Richard A. 3 563
Mar 05, 2024 Common Stock Sell Paulson Richard A. 3 573
Mar 01, 2024 Common Sell Rangwala Reshma 5 969
Click to get the best stock tips daily for free!

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics. Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezo... KPTI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT